|
Comparison of Two Kinds of Dendritic Cell Immunizations in Treating Melanoma Clinical Trials Resources presented on Clinical Trials Search is not meant to be a substitute for proven health advice, calls or treatment with a real medical. We aren't mDs. Always consult your doctor on Comparison of Two Kinds of Dendritic Cell Immunizations in Treating Melanoma conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Comparison of Two Kinds of Dendritic Cell Immunizations in Treating Melanoma Clinical research trials and Comparison of Two Kinds of Dendritic Cell Immunizations in Treating Melanoma healthcare trials take place in a lot of of localities throughout the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectiveness of new does drugs. The function of the studies / projects is to figure out specific human medical questions. Clinical trials are a popular means for doctors, government agencies, and private sector corporations to find cures for all varieties of conditions, like Comparison of Two Kinds of Dendritic Cell Immunizations in Treating Melanoma. Comparison of Two Kinds of Dendritic Cell Immunizations in Treating Melanoma Clinical Trials and other clinical trials allow volunteers to access health treatment options before they are available to the masses. Many times the subjects receive professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Comparison of Two Kinds of Dendritic Cell Immunizations in Treating Melanoma clinical trial. Human subjects often obtain the finest healthcare possible for their Comparison of Two Kinds of Dendritic Cell Immunizations in Treating Melanoma condition. Hazards are a reality, nevertheless, and might include additional or frequent dr. calls, health hazards (potentially life-jeopardizing), and/or the treatment being uneffective. Trials are federally regulated with stern guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "C" Clinical Trials Conditions > Comparison of Two Kinds of Dendritic Cell Immunizations in Treating Melanoma  Comparison of Two Kinds of Dendritic Cell Immunizations in Treating Melanoma
Comparison of Two Kinds of Dendritic Cell Immunizations in Treating Melanoma
For Condition: Melanoma,Neoplasm Metastasis
Status: Completed
Sponsor(s): National Cancer Institute (NCI) ,
Synopsis: This study will look at the safety and effectiveness of immunizations derived from two different substances in fighting melanoma. Both immunizations will contain dendritic cells-a type of cell that boosts immune system activity-but the cells will be produced by two different methods and their effects on the immune response compared. The body normally produces small amounts of dendritic cells, but large numbers of these cells can be made in the laboratory. In this study, one group of patients will receive dendritic cells derived from a type of white blood cell called monocytes, and a second group will receive cells derived from what are called stem cells. Small amounts of protein substances called gp100 and MART-1 that are found in most melanoma cells will be added to both types of dendritic cells. These protein substances may provoke the immune system to attack the tumor cells in much the same way a vaccine works. Patients in both groups will receive four cycles of immunizations four weeks apart. In the first two cycles, the cells will be injected into lymph vessels, and in the next two, they will be injected under the skin. Patients will also undergo apheresis-a procedure in which whole blood is drawn much like donating blood, but the lymphocytes are separated out by a machine and the rest of the blood is then returned to the body. This procedure may be repeated from two to four times during the study, depending on which immunization group the patient is in. Some patients may be asked to have a lymph node biopsy (removal of a few lymph nodes) to examine the effects of the dendritic cells. Some patients may also receive injections of a drug to boost white cell production.
Details: HLA-A201 positive patients with high risk stage III melanoma or completely resected metastatic melanoma will receive dendritic cells pulsed with peptides representing HLA-A201 restricted T cell epitopes of the melanoma antigens, MART-1:26-35(27L) and gp100. Dendritic cells will be administered intralymphatically for 2 cycles, then subcutaneously for 2 cycles. Patients will be randomized to receive either CD34-derived or peripheral monocyte derived dendritic cells. This study is designed to compare the immunologic effects of CD34-derived and peripheral monocyte derived dendritic cells.
Eligibility:
Study Type: Interventional, Treatment, Safety/Efficacy
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: Any HLA-201 positive patient with high risk stage III melanoma (greater than 3 lymph nodes positive) or completely resected metastatic melanoma within 6 months of surgical resection will be considered. Patients must be disease free at the time of protocol entry, as documented by radiologic studies including full body CT scans within 4 weeks of patient entry. Serum creatinine of 2.0 mg/dl or less. Bilirubin 1.6 mg/dl or less. WBC 3000/mm(3) or greater. Platelet count 90,000 mm(3) or greater. Serum AST/ALT less than three times normal. ECOG performance status of 0 or 1. 16 years old or greater. Patients or legal guardian must be able to provide an informed consent. Patients must not be undergoing or have undergone in the past month any other form of therapy except surgery for their cancer. Patients must not have active systemic infections, coagulation disorders, history of autoimmune disorders or other major medical illnesses of the cardiovascular or respiratory systems. Patients must not require systemic steroid therapy. Females must not be pregnant and/or breast feeding. Patients must not be known to be positive for hepatitis B(S)Ag, or HIV antibody. Patients must not have previously been immunized with MART-1:26-35(27L) or gp100 peptide, G9-209-2M.
Total Enrollment: 28
Location and Contact Information:
National Cancer Institute (NCI)
Bethesda, Maryland, 20892
United States
Additional Information:
Study ID Numbers: 990132; 99-C-0132
Study Start Date: July 7, 1999
Record last reviewed: May 14, 2002
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00001825
Other Neoplasm Metastasis Studies:
1. Immunization of HLA-A201 Patients with Metastatic Melanoma Using a Combination of Immunodominant Peptides from Three Melanoma Antigens, MART-1, GP100 and Tyrosinase
2. EPO906 Therapy in Patients with Advanced Melanoma
3. Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Melanoma
4. Biological Therapy in Treating Children With Refractory or Recurrent Neuroblastoma or Other Tumors
5. ADI-PEG in Patients With Metastatic Melanoma
Related Studies:
Other Neoplasm Metastasis Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
Comparison of Two Kinds of Dendritic Cell Immunizations in Treating Melanoma
|
|
|
|
|
|
|
|
